General
Preferred name
zidovudine
Synonyms
azidothymidine ()
NSC 602670 ()
ZDV ()
AZT ()
Zidovudine, AZT ()
ZIDOVUDINE SODIUM ()
Azidothymidine, NSC 602670,Retrovir ()
BW-A509U ()
COMPOUND-S ()
3'-azt ()
Retrovir ()
Zidovudine component of lamivudine/ teva ()
BWA509U ()
BW A509U ()
Zidovudine component of trizivir ()
Zidovudina ()
NSC-602670 ()
BW-A-509U ()
Compound S ()
Zidovudine component of combivir ()
Zidovudinum ()
P&D ID
PD003173
CAS
30516-87-1
Tags
available
prodrug
drug
Approved by
EMA
FDA
First approval
1987
Drug indication
Virus infection
HIV infection
Human immunodeficiency virus infection
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Zidovudine (AZT) is a nucleoside analogue reverse-transcriptase inhibitor (NRTI) class antiretroviral drug. It was the first antiretroviral for HIV to be approved by the US FDA, and it is now listed in the World Health Organization's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019).
(GtoPdb)
PRICE
29
DESCRIPTION
Cyclophilin A inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Zidovudine is a dideoxynucleoside compound. It is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. It is used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
(Enamine Bioactive Compounds)
DESCRIPTION
Zidovudine (ZDV) is a synthetic dideoxynucleoside. After intracellular phosphorylation to its active metabolite, zidovudine inhibits DNA polymerase, resulting in the inhibition of DNA replication and cell death. This agent also decreases levels of available pyrimidines.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
35
Organisms
12
Compound Sets
27
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
61
Molecular Weight
267.1
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
1
cLogP
-0.2
TPSA
133.08
Fraction CSP3
0.6
Chiral centers
3.0
Largest ring
6.0
QED
0.45
Structural alerts
1
azo_A(324)
[#7;!R]=[#7]
PAINS Family A
Related compounds
Custom attributes
(extracted from source data)
Target
CRISPR/Cas9
HIV
Reverse Transcriptase
Telomerase reverse transcriptase
TERT
NRT inhibitor
CRISPR/Cas9,Reverse Transcriptase
Primary Target
RNA/DNA Polymerase
MOA
Inhibitor
nucleoside reverse transcriptase inhibitor
Indication
human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)
Pathway
DNA Damage/DNA Repair
Microbiology/virology
Proteases/Proteasome
Therapeutic Class
Anti-HIV Agents
Source data
